Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
A phase 1/2 trial of Pembrolizumab, Sacituzumab tirumotecan, Capecitabine, Fluorouracil (5-FU), Oxaliplatin and Patritumab deruxtecan in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) is a phase 1/2 interventional study registered as NCT06469944 by Merck Sharp & Dohme LLC, with 160 participants planned, started 2024-09-20 and due to reach its primary completion in 2029-09-12. Interventions recorded: Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine, Leucovorin, Levoleucovorin and 5-Fluorouracil (5-FU).
Similar pages
not linked directly; found by shared links- TrialSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Shares Fluorouracil (5-FU), Oxaliplatin, Sacituzumab tirumotecan, Merck & Co. (MSD) and the tag pipeline.
- TrialA Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
Shares Fluorouracil (5-FU), Oxaliplatin, Capecitabine, Oesophageal cancer and the tag pipeline.
- TrialSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Shares Sacituzumab tirumotecan, Capecitabine, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Shares Fluorouracil (5-FU), Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Shares Sacituzumab tirumotecan, Capecitabine, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Oesophageal cancer, Pembrolizumab and the tag pipeline.
- TrialSubstudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Shares Fluorouracil (5-FU), Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.